CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer

[1]  A. Giuliano,et al.  Distinct Hypermethylation Profile of Primary Breast Cancer Is Associated with Sentinel Lymph Node Metastasis , 2005, Clinical Cancer Research.

[2]  M. Szyf,et al.  DNA methylation and breast cancer. , 2004, Biochemical pharmacology.

[3]  D. Seripa,et al.  Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors , 2004, Clinical Cancer Research.

[4]  D. Tripathy,et al.  Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. , 2004, The oncologist.

[5]  A. Cleton-Jansen,et al.  Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors. , 2004, Biochemical and biophysical research communications.

[6]  G. Birdsong,et al.  Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population , 2004, International Journal of Clinical Oncology.

[7]  R. Hazan,et al.  Cadherin Switch in Tumor Progression , 2004, Annals of the New York Academy of Sciences.

[8]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[9]  D. Welch,et al.  Genetic Basis of Human Breast Cancer Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[10]  G. Birdsong,et al.  Expression of e-cadherin in high-risk breast cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[11]  Trygve O. Tollefsbol,et al.  Aging, cancer and nutrition: the DNA methylation connection , 2003, Mechanisms of Ageing and Development.

[12]  I. Wong,et al.  Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. , 2003, Oncology reports.

[13]  Jan F. Silverman,et al.  Molecular Evolutionary Patterns in Breast Cancer , 2003, Advances in anatomic pathology.

[14]  C. Lopes,et al.  Detection of gene promoter hypermethylation in fine needle washings from breast lesions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  A. Wahed,et al.  E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma. , 2002, Annals of diagnostic pathology.

[16]  S. Toyooka,et al.  Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. , 2002, Cancer research.

[17]  H. Höfler,et al.  Genetic Alterations in Presumptive Precursor Lesions of Breast Carcinomas , 2002, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[18]  J. Herman,et al.  DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. , 2001, Human molecular genetics.

[19]  J. Herman,et al.  Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  N. Davidson,et al.  DNA methylation in breast cancer. , 2001, Endocrine-related cancer.

[21]  R. Roylance,et al.  Multiple ways of silencing E‐cadherin gene expression in lobular carcinoma of the breast , 2001, International journal of cancer.

[22]  I J Chalmers,et al.  Mapping the chromosome 16 cadherin gene cluster to a minimal deleted region in ductal breast cancer. , 2001, Cancer genetics and cytogenetics.

[23]  C. Mathew,et al.  Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. , 2001, Cancer research.

[24]  T. Rebbeck,et al.  Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. , 2001, American journal of clinical pathology.

[25]  P. Rocca-Serra,et al.  High-resolution integrated map encompassing the breast cancer loss of heterozygosity region on human chromosome 16q22.1. , 2000, Genomics.

[26]  J. Herman,et al.  E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[28]  J. Herman,et al.  Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.

[29]  J. Jónasson,et al.  Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. , 1999, European journal of cancer.

[30]  E. Fearon,et al.  Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements , 1999, Oncogene.

[31]  A. Marzo,et al.  Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. , 1999, Cancer research.

[32]  S. Markowitz,et al.  E‐cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer , 1999, Human mutation.

[33]  S. Hirohashi.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. , 1998, The American journal of pathology.

[34]  G. Bevilacqua,et al.  A region on the long arm of chromosome 16 is frequently deleted in metastatic node-negative breast cancer. , 1998, International journal of oncology.

[35]  S. Weitzman,et al.  Mapping of ER gene CpG island methylation-specific polymerase chain reaction. , 1998, Cancer research.

[36]  M. J. van de Vijver,et al.  Simultaneous loss of E‐cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ , 1997, The Journal of pathology.

[37]  R. Lidereau,et al.  Loss of heterozygosity on chromosome arm 16q in breast cancer metastases , 1997, Genes, chromosomes & cancer.

[38]  Dieter Niederacher,et al.  Multistep carcinogenesis of breast cancer and tumour heterogeneity , 1997, Journal of Molecular Medicine.

[39]  G. Berx,et al.  E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.

[40]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Weitzman,et al.  Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  W. Birchmeier,et al.  Mechanisms Identified in the Transcriptional Control of Epithelial Gene Expression (*) , 1996, The Journal of Biological Chemistry.

[43]  M. Ikura,et al.  Solution structure of the epithelial cadherin domain responsible for selective cell adhesion , 1995, Science.

[44]  A. Simpson,et al.  Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. , 1994, BioTechniques.

[45]  J. Taylor‐Papadimitriou,et al.  Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.